Acurx Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

12 Months Ended

Dec. 31, 2025

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of December 31, 2025 and 2024 were as follows:


		December 31, 2025			December 31, 2024
Accrued research and development		$	2,311,348		$	2,664,065
Accrued compensation expenses			39,011			537,630
Accrued professional fees			63,782			36,360
Other accounts payable and accrued expenses			6,802			4,787
Total		$	2,420,943		$	3,242,842